Teva Makes The Cut: 5,000 Jobs To Be Eliminated
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic drug manufacturer said it will accelerate its cost reduction program and shrink its global workforce by 5,000 employees amid slowing sales growth and the looming threat of competition to its blockbuster branded medicine, Copaxone.
You may also be interested in...
Teva Changes Its Tune On Substitutable Generic Advair
Teva is aggressively developing a fully substitutable generic version of Advair and other AB-rated respiratory products now that FDA has released draft guidance on bioequivalence requirements for the inhaled respiratory drug.
Chief Executive Change At Teva Illustrates Diversification Emphasis At Major Generic Drug Makers
Most of the top 20 generic drug makers are subsidiaries of diversified pharmas or smaller generics-only plays based in the Far East. But diversification, although long a goal, is now urgent for the three major independent generic firms – Teva, Mylan and Watson.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.